Entera Bio Ltd. (ENTX)
2.92
-0.10
(-3.31%)
USD |
NASDAQ |
Oct 23, 16:00
2.905
-0.02
(-0.51%)
After-Hours: 20:00
Entera Bio Enterprise Value : 125.92M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 125.92M |
| October 22, 2026 | 130.85M |
| October 21, 2026 | 132.33M |
| October 20, 2026 | 130.85M |
| October 19, 2026 | 126.91M |
| October 16, 2026 | 114.09M |
| October 15, 2026 | 118.53M |
| October 14, 2026 | 105.22M |
| October 13, 2026 | 104.73M |
| October 12, 2026 | 112.61M |
| October 09, 2026 | 113.11M |
| October 08, 2026 | 105.22M |
| October 07, 2026 | 105.71M |
| October 06, 2026 | 106.70M |
| October 05, 2026 | 111.13M |
| October 02, 2026 | 122.96M |
| October 01, 2026 | 124.44M |
| September 30, 2026 | 125.43M |
| September 29, 2026 | 114.58M |
| September 28, 2026 | 114.58M |
| September 25, 2026 | 117.30M |
| September 24, 2026 | 120.01M |
| September 23, 2026 | 120.50M |
| September 22, 2026 | 128.88M |
| September 21, 2026 | 127.89M |
| Date | Value |
|---|---|
| September 18, 2026 | 127.89M |
| September 17, 2026 | 131.34M |
| September 16, 2026 | 127.89M |
| September 15, 2026 | 122.96M |
| September 14, 2026 | 120.99M |
| September 11, 2026 | 121.98M |
| September 10, 2026 | 119.51M |
| September 09, 2026 | 121.98M |
| September 08, 2026 | 130.36M |
| September 04, 2026 | 129.86M |
| September 03, 2026 | 127.40M |
| September 02, 2026 | 125.92M |
| September 01, 2026 | 124.94M |
| August 31, 2026 | 127.40M |
| August 28, 2026 | 131.34M |
| August 27, 2026 | 133.81M |
| August 26, 2026 | 139.23M |
| August 25, 2026 | 153.03M |
| August 24, 2026 | 150.57M |
| August 21, 2026 | 141.20M |
| August 20, 2026 | 140.71M |
| August 19, 2026 | 135.29M |
| August 18, 2026 | 124.44M |
| August 17, 2026 | 124.94M |
| August 14, 2026 | 124.44M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| BioLineRx Ltd. | 6.623M |
| XTL Biopharmaceuticals Ltd. | -- |
| Kamada Ltd. | 389.95M |
| Can-Fite BioPharma Ltd. | -5.068M |
| Eocene Ltd. | -8.227M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.312M |
| Total Expenses (Quarterly) | 7.312M |
| EPS Diluted (Quarterly) | -0.1449 |
| Earnings Yield | -12.04% |
| Normalized Earnings Yield | -12.04 |